[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-459323-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-459323-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comparison-of-a-blood-based-mitochondrial-biomarker-with-plasma-atn-performance-poster-presentation","Comparison of a blood based mitochondrial biomarker with plasma ATN performance - poster presentation","","Background: Alzheimer’s disease pathology begins decades before dementia symptoms. Amyloid beta (Aβ) accumulates first in cognitively normal individuals, followed by tau and cognitive changes, and prior studies link these processes to metabolic and mitochondrial outcomes. Method: Blood cells were collected from 20 cognitively normal, 20 mild-cognitive impairment, and 19 Alzheimer’s disease participants, stained with mitochondrial and apoptotic markers, quantified by flow cytometry, and summarized using the mitochondrial health index (MHI). Plasma biomarkers including NfL, pTau181, Aβ, and GFAP were measured with SIMOA, with APOE genotypes determined by Taqman assays. Result: MHI was reduced in AD and predicted later MMSE decline in MCI; APOE ε4 carriers showed lower MHI. Plasma GFAP, NfL, and pTau181 increased in AD. Conclusion: The MHI is a blood-based biomarker with reasonable discrimination for AD diagnosis and may support future therapeutic trial assessment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comparison-of-a-blood-based-mitochondrial-biomarker-with-plasma-atn-performance-poster-presentation/459323/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comparison-of-a-blood-based-mitochondrial-biomarker-with-plasma-atn-performance-poster-presentation/459323.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main comparison in this poster presentation?","Question",{"text":63,"@type":64},"It compares a blood-based mitochondrial biomarker summarized by the mitochondrial health index (MHI) with plasma ATN performance for Alzheimer’s disease-related discrimination.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were subjects grouped for the study?",{"text":68,"@type":64},"Participants were recruited into three diagnostic groups: cognitively normal (ND), mild-cognitive impairment (MCI), and Alzheimer’s disease (AD).",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings about the MHI biomarker and plasma markers?",{"text":72,"@type":64},"MHI was significantly reduced in AD, and in MCI it predicted later MMSE decline; APOE ε4 carriers had reduced MHI across diagnoses. Plasma GFAP, NfL, and pTau181 were increased in AD.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},459323,1790755686,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":80,"read_time":55,"preview_page_count":4},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10. 1002/alz70856_106233  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nComparison of a blood based mitochondrial biomarker with plasma ATN performance  \nBrittany M Hauger 1  Keith P Smith2  Taylor A. Strope 1, 3  Ellen Oehmke 1  Paul J Kueck4, 5, 6  Riley E Kemna3, 4  Casey S. John3, 4  Leonidas Bantis3  Jill K Morris4, 7  Russell H Swerdlow3, 4, 8, 9, 10  Heather M Wilkins1, 3  \n1 University of Kansas Alzheimer’s Disease Research Center, Kansas City, KS, USA  \n2 3901 rainbow blvd, Kansas City, KS, USA  \n3 University of Kansas Medical Center, Kansas City, KS, USA  \n4 University of Kansas Alzheimer’s Disease Research Center, Fairway, KS, USA  \n5 University of Kansas Alzheimer’s Disease Center, Fairway, KS, USA  \n6 Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA  \n7 University of Kansas Medical Center, Alzheimer’s Disease Research Center, Fairway, KS, USA  \n8 Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS, USA  \n9 Department of Cell Biology and Physiology, University of Kansas Medical Center, Kansas City, KS, USA  \n10 Department of Neurology, University of Kansas School of Medicine, Kansas City, KS, USA  \nCorrespondence  \nHeather M Wilkins, University of Kansas Alzheimer’s Disease Research Center, Kansas City, KS, USA.  \nEmail: hwi[lkins@kumc.edu](lkins@kumc.edu)  \nAbstract  \nBackground: Alzheimer’s disease (AD) pathology begins decades before clinical onset of dementia. Amyloid beta (Aβ) generally accumulates first in cognitively normal (ND) individuals, with tau and cognitive abnormalities following. AD pathologies have been found to correlate and interact with metabolic and mitochondrial outcomes in studies spanning numerous experimental paradigms. Targeting metabolic and mitochondrial function in clinical trials is an emerging theme for AD and highlights the importance and need for biomarkers which measure mitochondrial function.  \nMethod: 20 ND, 20 mild-cognitive impairment, and 19 Alzheimer’s Disease (AD) subjects were recruited from the KU Alzheimer’s Disease Research Center Clinical Cohort. Blood was collected in ACD tubes. Lymphocytes were isolated using Accuspin tubes, histopaque 1077, and centrifugation. Lymphocytes were stained with MitoTracker/Annexin V, MitoSox/Hoechst, and TMRE/Hoechst. Fluorescent cells were quantified using flow cytometry and values normalized to Hoechst. Fluorescent measures were completed within 30 hours of blood draw. The mitochondrial health index (MHI) algorithm was calculated. Plasma NfL, pTau181, Aβ, and GFAP were determined using SIMOA. APOE genotypes were determined using a Taqman allelic discrimination assay.  \nResult: The MHI biomarker was significantly reduced in AD subjects. In MCI subjects, the MHI predicted a later reduction in mini mental state exam (MMSE) scores. APOE ε4 carriers had reduced MHI regardless of diagnosis. Plasma GFAP, NfL, and pTau181 were increased in AD subjects. ROC analysis for individual biomarkers for ND/AD: Aβ 0. 6658, GFAP 0.7194, NfL 0.7194, pTau181 0.7796, MHI 0.8028. ROC analysis for individual biomarkers for ND/MCI: Aβ 0.6700, GFAP 0.5737, NfL 0.5368, pTau181 0.7105, MHI 0.6025. ROC analysis for individual biomarkers for MCI/AD: Aβ 0.5632,  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e106233.  \n[https://doi.org/10.1002/alz70856_106233](https://doi.org/10.1002/alz70856_106233)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of2  \nBIOMARKERS  \nGFAP0.5965, NfL0.6462, pTau1810.5078, MHI0.8139. CombiningtheMHIwithATNin an algorithm improved ROC, however including Aβ in the algorithm wor","cbCaivz0pXwdPeg2","https://ap.wps.com/l/cbCaivz0pXwdPeg2","pdf",95579,"English","# Poster Presentation: Biomarkers (Non-Neuroimaging)\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"What is the main comparison in this poster presentation?\",\"answer\":\"It compares a blood-based mitochondrial biomarker summarized by the mitochondrial health index (MHI) with plasma ATN performance for Alzheimer’s disease-related discrimination.\"},{\"question\":\"How were subjects grouped for the study?\",\"answer\":\"Participants were recruited into three diagnostic groups: cognitively normal (ND), mild-cognitive impairment (MCI), and Alzheimer’s disease (AD).\"},{\"question\":\"What were the key findings about the MHI biomarker and plasma markers?\",\"answer\":\"MHI was significantly reduced in AD, and in MCI it predicted later MMSE decline; APOE ε4 carriers had reduced MHI across diagnoses. Plasma GFAP, NfL, and pTau181 were increased in AD.\"}]","Comparison of a blood based mitochondrial biomarker with plasma ATN performance - poster presentation | PDF"]